GenVec Signs New Contract to Support HIV and Influenza Vaccine Development

GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq:
GNVC) announced today that SAIC-Frederick, Inc. has signed a contract with
GenVec for the development of influenza and HIV vaccines in support of the
Vaccine Research Center (VRC) of the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
This four-year contract has a total value of over $22 million if all options
are exercised. Over the next year, GenVec will receive approximately $2.6
million.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )

Under the contract, the vaccines would be comprised of genetic material
supplied by the VRC and adenoviral vectors supplied by GenVec.

"This new contract supports important efforts in HIV and influenza. Given the
heightened concerns about influenza, this contract is timely and we look
forward to applying our novel technology to this problem," stated Dr. Paul
Fischer, GenVec's President and CEO. "In particular, we are looking forward to
working on a universal flu vaccine, which has the potential to protect against
seasonal and pandemic outbreaks."

Work under this contract will include generation of HIV vaccine candidates,
generation of a universal flu vaccine candidate, process and assay development
for manufacture of vaccine candidates for clinical testing, and continued
support of the HIV vaccine candidates currently in clinical testing.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs
and vaccines. GenVec's lead product TNFerade is currently in a pivotal
clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also
been and is currently being evaluated for its potential use in the treatment
of several other cancers including esophageal cancer, rectal cancer, and head
and neck cancer. GenVec also uses its proprietary adenovector technology to
develop vaccines for infectious diseases including HIV, malaria,
foot-and-mouth disease, influenza, respiratory syncytial virus (RSV), and
HSV-2. Additional information about GenVec is available at www.genvec.com and
in the company's various filings with the Securities and Exchange Commission.

About the VRC

The Dale and Betty Bumpers Vaccine Research Center (VRC) at the National
Institutes of Health was established to facilitate research in vaccine
development. The VRC is dedicated to improving global human health through the
rigorous pursuit of effective vaccines for human diseases. Established by
former President Bill Clinton as part of an initiative to develop an AIDS
vaccine, the VRC is a unique venture within the NIH intramural research
program. Initially spearheaded by the National Institute of Allergy and
Infectious Diseases (NIAID), the National Cancer Institute, and the NIH Office
of AIDS Research, the VRC is now part of the NIAID organization.

About SAIC-Frederick

SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications
International Corporation (SAIC), a Fortune 500® company, is the operations
and technical support contractor for the National Cancer Institute's research
and development center in Frederick, Md. This is a national laboratory
dedicated to rapidly translating basic research into new technologies for
diagnosing, treating, and preventing cancer and AIDS. SAIC-Frederick maintains
a full suite of advanced technologies in areas such as nanotechnology,
genomics and imaging; operates the federal government's drug and vaccine
manufacturing facilities (VRC's Vaccine Pilot Plant and Biopharmaceutical
Development Program); operates the high-performance Advanced Biomedical
Computing Center; and supports more than 300 clinical trials for patients in
the United States and around the world.

This project is being wholly funded with Federal funds from the National
Cancer Institute, National Institutes of Health under Contract No.
HHSN261200800001E. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government.

Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding future revenues and operating expenses, are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act. GenVec cautions that these forward-looking statements
are subject to numerous assumptions, risks and uncertainties, which change
over time. Factors that may cause actual results to differ materially from
the results discussed in the forward-looking statements or historical
experience include risks and uncertainties, including the failure by GenVec to
secure and maintain relationships with collaborators; risks relating to the
early stage of GenVec's product candidates under development; uncertainties
relating to clinical trials; risks relating to the commercialization, if any,
of GenVec's proposed product candidates; dependence on the efforts of third
parties; dependence on intellectual property; and risks that we may lack the
financial resources and access to capital to fund our operations. Further
information on the factors and risks that could affect GenVec's business,
financial conditions and results of operations, are contained in GenVec's
filings with the U.S. Securities and Exchange Commission (SEC), which are
available at www.sec.gov. These forward-looking statements speak only as of
the date of this press release, and GenVec assumes no duty to update
forward-looking statements.

Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
(301) 944-1877 (212) 827-0020
ddipirro@genvec.com amielach@tiberendstrategicadvisors.com

SOURCE GenVec, Inc.

Investor Contact, Danielle M. DiPirro of GenVec, Inc., +1-301-944-1877,
ddipirro@genvec.com; or Media Contact, Andrew Mielach of Tiberend Strategic
Advisors, Inc., +1-212-827-0020, amielach@tiberendstrategicadvisors.com